Comments for HEPH - Stockpickr! Your Source for Stock Ideas

Comments for HEPH

Added By	Comments	Type	Date Added
barrons2	Market Outperform - Price: $1.54 on July 15 by Rodman & Renshaw Hollis-Eden Pharmaceuticals today announced the commencement of a Phase II clinical trial with Triolex in patients with Type 2 diabetes (T2D). The advancement of Triolex (formerly HE3286) into clinical evaluation in T2D comes, as expected, on the heels of positive interim results from the ongoing Phase I/II study with Triolex in obese adult subjects, which the company reported last month during the American Diabetes Association 2008 Scientific Sessions. The interim Phase I/II data showed that obese patients treated with oral Triolex for 28 days demonstrated significantly improved insulin sensitivity, and lower fasting plasma glucose, insulin and triglyceride levels, compared to placebo-treated patients. We believe that Triolex has the potential to be a safe, novel, first-in-class insulin sensitizer. We therefore reiterate our Market Outperform rating and year-end price target of $6...and continue to recommend HEPH as our top small-cap idea for long-term investors.	Love	July 19, 2008
Dabbler	Took a beating when HHS pulled the rug out from underneath the company.	Hate	May 23, 2007
jtucker.us	speculation and opportunistic	Love	March 22, 2007
rdayle	LIKE THE PRODUCTS IT IS DEVELOPING	Love	March 21, 2007
beechman	short term profit	Love	February 27, 2007
nswlnm	upside potential	Love	February 14, 2007
MnM4Christ	About time Neummune gets Project Bioshield approval with increasing threats of NUKE a WHEN not IF proposition. Also, novel IMMUNOLOGY boosting approach. Even against super bacterial to increase neutrophil and platlet levels against Hospital acquired infections.	Love	February 09, 2007
robert fernandez	I LIKE the small bio stocks	Love	January 31, 2007
David Krick	Speculation in bio	Love	January 08, 2007